First Trust Advisors’s Tvardi Therapeutics TVRD Stock Holding History

First Trust Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-485	Closed	-$282K	–	2440
2019 Q4	$282K	Buy	+485	New	+$340K	﹤0.01%	2289

Other funds holding TVRD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

First Trust Advisors's TVRD Position: Q1 2020 in Review

First Trust Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 485 shares — an estimated $282K sold.

First Trust Advisors first reported a position in TVRD in Q4 2019 and held it in 1 quarter. The position peaked at $282K in Q4 2019. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

First Trust Advisors reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
First Trust Advisors sold 485 Tvardi Therapeutics shares in Q1 2020, an estimated $282K.
First Trust Advisors first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 1 quarter.
First Trust Advisors's Tvardi Therapeutics position peaked at $282K in Q4 2019.
133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on First Trust Advisors's 13F filing for Q1 2020, filed 6 May 2020.